SAN DIEGO, Sept. 23 /PRNewswire-FirstCall/ -- Accelrys, Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP) and active member of the Oracle PartnerNetwork, today announced a strategic agreement in which Accelrys will embed Oracle(R) technology into Accelrys' Discovery Studio(R) family of products. Under the terms of the agreement, Accelrys will embed Oracle(R) Database and associated software in Discovery Studio Project Knowledge Manager Plus (DS ProjectKM Plus), the core component of Accelrys' Discovery Studio's knowledge-centric system. Accelrys will resell the Oracle Database, and will facilitate the seamless integration of Oracle for all Discovery Studio related data management needs -- for both individual workstations and at the enterprise level. "Accelrys is a leading provider of life science discovery software and we are pleased that they have chosen to embed Oracle technology into Discovery Studio," said Robert Shimp, vice president, Platform Marketing at Oracle. "Oracle Database is already the database of choice for life sciences infrastructure. This relationship will extend the availability of next-generation technology to a new class of researchers." "This agreement emphasizes Accelrys' commitment to ensuring that our customers have a cost effective way to apply the technology best suited to their needs," said Mark Emkjer, president of Accelrys. "The combination of Accelrys and Oracle in DS ProjectKM Plus will allow research scientists in the chemical and pharmaceutical industries to benefit from Accelrys' expertise as one of the leading developers of scientific software, as well as from the reliability and security features of the Oracle Database, the Life Sciences industry standard for data storage." DS ProjectKM Plus facilitates the exchange of information between researchers, breaking down the barriers between scientific disciplines that ordinarily restrict collaboration. Data and results from across a research organization, together with their often-complex inter-relationships, are captured in a central database. Provided a user has the proper security permissions, he or she can quickly find relevant data that otherwise might previously have been inaccessible. Such secure exchange will improve the R&D process behind the design and development of novel drugs, chemicals, and materials. DS ProjectKM Plus will be available to commercial customers along with Discovery Studio Modeling v1.1, available October 2003. About Discovery Studio Discovery Studio is a powerful research environment for the life sciences that delivers a comprehensive suite of informatics, modeling, and simulation solutions. This environment is composed of a wide breadth of tools, client-server applications, and databases for handling the specific research problems encountered by scientists working in the discovery process. The Discovery Studio design enables collaboration across scientific disciplines through a centralized project and knowledge management system, connecting the research conducted by biologists and chemists. In addition, Discovery Studio is an open platform built on industry-standard components so that it can leverage existing IT infrastructure and the integration of third-party applications, public domain, and other in-house developed applications. More information on Discovery Studio can be found at http://www.discovery-studio.com/ About the Oracle PartnerNetwork The Oracle PartnerNetwork is a global business network of more than 12,000 companies who deliver innovative enterprise software solutions based on Oracle software. Through access to Oracle's premier products, education, technical services, marketing and sales support, the Oracle PartnerNetwork provides partners with the resources they need to be successful in today's Internet economy. Oracle partners are able to offer customers leading-edge solutions backed by Oracle's position as the world's largest enterprise software company. About Accelrys Accelrys is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists, and materials scientists for product design, drug discovery, and development. Accelrys' platform technology and consulting services enable enterprise-wide solutions tailored to today's leading research organizations. The company's two main centers of excellence are in San Diego, and Cambridge, UK. These centers combine research and product development with facilities to support significant collaborative projects. Accelrys is a subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP). More information on Accelrys can be found at http://www.accelrys.com. Oracle is a registered trademark of Oracle Corporation and/or its affiliates. When used anywhere in this document, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Pharmacopeia's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Public Relations Contacts: Jim Rivas Accelrys, Inc. (858) 799-5393 firstname.lastname@example.org
SOURCE Accelrys, Inc.